on 01 Jan 2025
Last Applicant/ Owned by
Route 206 & Province Line Road
Princeton
NJ
08543
Serial Number
98397734 filed on 08th Feb 2024
Registration Number
N/A
Correspondent Address
Marilyn F. Kelly
Marilyn F. Kelly Bristol-Myers Squibb Company
Trademark Dept., Mailstop D. 4243
Princeton, NJ 08648-4000
United States
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloprol Read More
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical and biological preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use, namely, for the treatment of neuropsychiatric disorders; Pharmaceutical preparations for human use, namely, therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors, diagnostic radiopharmaceutical preparations, diagnostic agents, preparations and substances for medical purposes; Pharmaceutical preparations for human use, namely, radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer, radio-isotope markers for therapeutic or diagnostic use.
N/A
N/A
No 98397734
No Service/Collective Mark
No 00163219-US
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
30th Dec 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
03rd Dec 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
03rd Dec 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
03rd Dec 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
03rd Sep 2024 | NON-FINAL ACTION E-MAILED |
03rd Sep 2024 | NON-FINAL ACTION WRITTEN |
03rd Sep 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
28th Aug 2024 | ASSIGNED TO EXAMINER |
07th Jun 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
08th Feb 2024 | NEW APPLICATION ENTERED |